• Dr. Rao is completing his own study comparing exercise and cognitive training in a different group of people.

    WSJ: Exercise Might Beat Puzzles for Protecting the Aging Brain

  • Results of a study comparing the two strategies in nearly 5, 000 patients aren't expected until at least 2014.

    WSJ: New Scrutiny for Popular Breast-Cancer Treatment

  • The results of a much-watched study comparing stents and drugs were revealed at a Boston Scientific meeting Sunday night.

    FORBES: Magazine Article

  • Still, he is co-leader of the major study comparing it to whole-breast irradiation.

    WSJ: New Scrutiny for Popular Breast-Cancer Treatment

  • They are also conducting a study comparing their medicine combined with chemotherapy versus a combination of Avastin, panitumumab and chemo.

    FORBES

  • By comparison, the patients in the ENHANCE study comparing Vytorin and Zocor had arteries that were only 0.7 mm thick.

    FORBES: Magazine Article

  • Merck and Schering-Plough are funding an 18, 000 patient study comparing Vytorin and Zocor that could settle all the debate for good.

    FORBES: Magazine Article

  • In the most recent issue of the journal Circulation, researchers published a 600-patient study comparing angioplasty, open-heart surgery, and treatment with medicines.

    FORBES: Study Could Hurt Stent Sales

  • Back in 2001, a plan was in the works for a study comparing Erbitux combined with chemotherapy to chemo alone for front-line use.

    FORBES: ImClone's Next Hurdles: Cost And Competition

  • For arthritis drugs, data is most likely to come from a Pfizer-sponsored study comparing the heart safety of Celebrex with ibuprofen and naproxen.

    FORBES: Magazine Article

  • Pfizer has enlisted Nissen to conduct a giant study comparing Celebrex, ibuprofen and naproxen, but results are not expected until at least 2009.

    FORBES: Magazine Article

  • Merck decided to push forward with Arcoxia after the results of a big study comparing its cardiovascular risk with Voltaren, or diclofenac, from Novartis.

    FORBES: Magazine Article

  • He is helping to head up a 10, 000-patient study comparing Vytorin and Zetia for preventing heart attacks, strokes and deaths, with results expected in 2011.

    FORBES: What's Next For Vytorin?

  • Now the FDA has told Merck it should wait until a 20, 000-patient study comparing Cordaptive to a placebo in patients who are also taking the cholesterol drug Zocor.

    FORBES: Is Merck Flying Blind?

  • Perhaps the most damning finding of all, though, comes from comparing the British study's results with those of the yet-to-be-published article on the performance of American mutual funds.

    ECONOMIST: Mutual suspicion

  • Urbanchuk did a study comparing a price hike for oil against the same price hike for corn, which in some form or another shows up in a lot of food.

    NPR: Energy Costs Drive Up Prices of Nearly Everything

  • Cleveland Clinic cardiologist Steven Nissen, an early critic of Zetia, says the Food and Drug Administration should have demanded Merck begin a giant study comparing Zetia with placebo immediately upon approval.

    FORBES: Pharmaceuticals

  • In a study comparing 22 organic farms with nearby conventional ones, birds did better on organic farms in 50 out of 68 cases, though the numbers were significant for only two species.

    ECONOMIST: What the birds and bees say

  • The results were shown in the first randomized phase II study comparing trastuzumab-DM1 (T-DM1) to Herceptin (trastuzumab) plus chemotherapy (docetaxel), the current standard of care for first line HER2-positive metastatic breast cancer.

    FORBES: Novartis Deal Bolsters Immunogen

  • The New England Journal of Medicine recently published a study comparing the ease of getting an appointment with a specialist in Cook County, Illinois, for children with Medicaid versus those with private insurance.

    FORBES: ObamaCare's Imposition Will Lead To An Unhealthy State Of Wellbeing

  • David Graham, an FDA drug safety researcher who played a key role in the Vioxx saga, published a study comparing Avandia to its main competitor, Actos, in a quarter of a million Medicare patients.

    FORBES: Why Avandia Will Change The Drug Industry

  • Merck decided to push forward with Arcoxia after the results of a big study comparing its cardiovascular risk with Voltaren, or diclofenac, from Novartis (nyse: NVS - news - people ).

    FORBES: What Was Merck Thinking?

  • He points out that a study comparing a weak cholesterol drug to a powerful one would show no difference if only a few patients were studied, even if the powerful drug was in fact superior.

    FORBES: Bristol Prepares Shot In Statin War

  • One study comparing northern Scotland with the Chilterns, both areas where red kites (one of Britain's rarer raptors) were reintroduced in 1989, found only 41 Scottish pairs by 2006 but 320 in the southern English hills.

    ECONOMIST: Technology to the rescue

  • Privately held firms also account for about 54.5 percent of spending on plants and equipment, professors John Asker and Alexander Ljungqvist of NYU and Joan Farre-Mensa of Harvard estimated in a recent study comparing private- and public-company investments.

    FORBES: Private companies pull economy along

  • Today the New England Journal of Medicine has published a Spanish study comparing two versions of the Mediterranean diet with a low fat diet and the result is important news if you are interested in reducing your risk of heart disease and stroke.

    FORBES: ?Ol��! How the New Spanish Study Should Change Your Diet

  • This 500-patient study is comparing Provenge to a placebo version of the treatments.

    FORBES: Magazine Article

  • Compiled by researchers in the US, the Timss study is an important benchmark for comparing standards in maths and science around the world.

    BBC: Science and maths skills warning

  • He says he is worried that although Merck is conducting a big 20, 000-patient study of Cordaptive, it is comparing the drug to placebo, not niacin.

    FORBES: Magazine Article

  • The Credo study has been criticised for not comparing the results of children who have won charter-school lotteries with those who have not a natural experiment in which the only difference between winners and losers should be the schooling they receive.

    ECONOMIST: Education: Charting a better course | The

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定